Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML

Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells

(2019) Puneet Agarwal et al.   Cell Stem Cell

Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease

(2018) Susan Branford et al.   BLOOD

Enhancer of zeste homolog 2 (EZH2) inhibitors

(2018) Nitya Gulati et al.   LEUKEMIA & LYMPHOMA

DNA methylation profiling reveals a pathological signature that contributes to transcriptional defects of CD34+ CD15− cells in early chronic-phase chronic myeloid leukemia

(2018) Stéphanie Maupetit-Mehouas et al.   Molecular Oncology

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers

(2018) Janeta Popovici-Muller et al.   ACS Medicinal Chemistry Letters

Six Years (2012–2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2‐Pyridone Compounds

(2018) Rossella Fioravanti et al.   CHEMICAL RECORD

Polycomb complexes in normal and malignant hematopoiesis

(2018) Valerio Di Carlo et al.   JOURNAL OF CELL BIOLOGY

Targeting glioma stem cells through combined BMI1 and EZH2 inhibition

(2017) Xun Jin et al.   NATURE MEDICINE

Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia

(2017) Alice Giustacchini et al.   NATURE MEDICINE

Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells

(2017) H S Madapura et al.   ONCOGENE

Epigenetic dysregulation in chronic myeloid leukaemia: A myriad of mechanisms and therapeutic options

(2017) Steffen Koschmieder et al.   SEMINARS IN CANCER BIOLOGY

The polycomb group protein BMI-1 inhibitor PTC-209 is a potent anti-myeloma agent alone or in combination with epigenetic inhibitors targeting EZH2 and the BET bromodomains

(2017) Mohammad Alzrigat et al.   Oncotarget

Downregulation of Bmi1 in breast cancer stem cells suppresses tumor growth and proliferation

(2017) Mathangi Srinivasan et al.   Oncotarget

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

(2017) Muhammad Rauzan et al.   PLoS One

Intestinal cancer stem cells marked by Bmi1 or Lgr5 expression contribute to tumor propagation via clonal expansion

(2017) Hirotsugu Yanai et al.   Scientific Reports

EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis

(2016) Wendy Béguelin et al.   CANCER CELL

The epigenetics of tumour initiation: cancer stem cells and their chromatin

(2016) Alexandra Avgustinova et al.   CURRENT OPINION IN GENETICS & DEVELOPMENT

Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma

(2016) Mariano G. Cardenas et al.   JOURNAL OF CLINICAL INVESTIGATION

CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia

(2016) Carsten Riether et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Next-generation sequencing identifies major DNA methylation changes during progression of Ph+ chronic myeloid leukemia

(2016) G Heller et al.   LEUKEMIA

BCR/ABL increases EZH2 levels which regulates XIAP expression via miRNA-219 in chronic myeloid leukemia cells

(2016) Chie Nishioka et al.   LEUKEMIA RESEARCH

Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution

(2016) M Ryan Corces et al.   NATURE GENETICS

Epigenetic control of adult stem cell function

(2016) Alexandra Avgustinova et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition

(2016) M. T. Scott et al.   Cancer Discovery

Chronic Myelogenous Leukemia- Initiating Cells Require Polycomb Group Protein EZH2

(2016) H. Xie et al.   Cancer Discovery

Leukemic stem cell persistence in chronic myeloid leukemia patients in deep molecular response induced by tyrosine kinase inhibitors and the impact of therapy discontinuation

(2016) Jean Claude Chomel et al.   Oncotarget

Epigenetics and aging

(2016) S. Pal et al.   Science Advances

DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders

(2016) Hanae Sato et al.   Frontiers in Oncology

Acquired somatic mutations of isocitrate dehydrogenases 1 and 2 (IDH1 and IDH2) in preleukemic disorders

(2015) Sadudee Chotirat et al.   BLOOD CELLS MOLECULES AND DISEASES

An exploratory double-blind, randomized clinical trial with selisistat, a SirT1 inhibitor, in patients with Huntington's disease

(2015) Sigurd D. Süssmuth et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Selective Sirtuin 1 Activator SRT2104 Reduces Endotoxin-Induced Cytokine Release and Coagulation Activation in Humans*

(2015) Anne J. van der Meer et al.   CRITICAL CARE MEDICINE

miRNAs as Biomarkers in Chronic Myelogenous Leukemia

(2015) Kasuen Kotagama et al.   DRUG DEVELOPMENT RESEARCH

Epigenetic aberrations in acute myeloid leukemia: Early key events during leukemogenesis

(2015) Anna Eriksson et al.   EXPERIMENTAL HEMATOLOGY

The BMI1 polycomb protein represses cyclin G2-induced autophagy to support proliferation in chronic myeloid leukemia cells

(2015) L Mourgues et al.   LEUKEMIA

Deacetylation of Nuclear LC3 Drives Autophagy Initiation under Starvation

(2015) Rui Huang et al.   MOLECULAR CELL

The roles of microRNAs in the pathogenesis and drug resistance of chronic myelogenous leukemia (Review)

(2015) CARLA DI STEFANO et al.   ONCOLOGY REPORTS

Tyrosine kinase inhibitor–induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling

(2015) Carsten Riether et al.   Science Translational Medicine

Dissecting the role of aberrant DNA methylation in human leukaemia

(2015) Giovanni Amabile et al.   Nature Communications

BMI1 gene expression in myeloid leukemias and its impact on prognosis

(2014) Niveen S. Saudy et al.   BLOOD CELLS MOLECULES AND DISEASES

Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

(2014) M Schmidt et al.   LEUKEMIA

Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia

(2014) Liran I. Shlush et al.   NATURE

The Role of BMI1 as a Biomarker of Cancer Stem Cells in Head and Neck Cancer: A Review

(2014) Eugenia Allegra et al.   ONCOLOGY

Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission

(2014) M. R. Corces-Zimmerman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Antiproliferative Activity of Kinase Inhibitors in Chronic Myeloid Leukemia Cells Is Mediated by FOXO Transcription Factors

(2014) Francesca Pellicano et al.   STEM CELLS

Methylation analysis of the DAPK1 gene in imatinib-resistant chronic myeloid leukemia patients

(2014) SELCEN CELIK et al.   Oncology Letters

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

(2013) M. Baccarani et al.   BLOOD

Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

(2013) D. M. Ross et al.   BLOOD

Roles of SIRT1 in leukemogenesis

(2013) WenYong Chen et al.   CURRENT OPINION IN HEMATOLOGY

The roles of epigenetic modifications of proapoptotic BID and BIM genes in imatinib-resistant chronic myeloid leukemia cells

(2013) Süreyya Bozkurt et al.   Hematology

EZH2 in normal and malignant hematopoiesis

(2013) K Lund et al.   LEUKEMIA

Imatinib induces demethylation of miR-203 gene: An epigenetic mechanism of anti-tumor effect of imatinib

(2013) Tatsuki Shibuta et al.   LEUKEMIA RESEARCH

Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia

(2013) Sureyya Bozkurt et al.   MEDICAL ONCOLOGY

Knockdown of Bmi1 inhibits the stemness properties and tumorigenicity of human bladder cancer stem cell-like side population cells

(2013) DINGJUN ZHU et al.   ONCOLOGY REPORTS

ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia

(2013) J Menezes et al.   Blood Cancer Journal

A Hybrid Mechanism of Action for BCL6 in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters

(2013) Katerina Hatzi et al.   Cell Reports

Role of Epigenetics in Chronic Myeloid Leukemia

(2013) Katerina Machova Polakova et al.   Current Hematologic Malignancy Reports

Increased acetylation of lysine 317/320 of p53 caused by BCR-ABL protects from cytoplasmic translocation of p53 and mitochondria-dependent apoptosis in response to DNA damage

(2012) Monika Kusio-Kobialka et al.   APOPTOSIS

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

(2012) H. J. Khoury et al.   BLOOD

Pharmacokinetics and tolerability of SRT2104, a first-in-class small molecule activator of SIRT1, after single and repeated oral administration in man

(2012) Ethan Hoffmann et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Activation of p53 by SIRT1 Inhibition Enhances Elimination of CML Leukemia Stem Cells in Combination with Imatinib

(2012) Ling Li et al.   CANCER CELL

Ezh1 Is Required for Hematopoietic Stem Cell Maintenance and Prevents Senescence-like Cell Cycle Arrest

(2012) Isabel Hidalgo et al.   Cell Stem Cell

Histone deacetylases inhibitor sodium butyrate inhibits JAK2/STAT signaling through upregulation of SOCS1 and SOCS3 mediated by HDAC8 inhibition in myeloproliferative neoplasms

(2012) Shen-meng Gao et al.   EXPERIMENTAL HEMATOLOGY

CD27 signaling on chronic myelogenous leukemia stem cells activates Wnt target genes and promotes disease progression

(2012) Christian Schürch et al.   JOURNAL OF CLINICAL INVESTIGATION

IDH mutation impairs histone demethylation and results in a block to cell differentiation

(2012) Chao Lu et al.   NATURE

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer

(2012) King Pan Ng et al.   NATURE MEDICINE

BCL6 controls neurogenesis through Sirt1-dependent epigenetic repression of selective Notch targets

(2012) Luca Tiberi et al.   NATURE NEUROSCIENCE

SIRT1 deacetylase promotes acquisition of genetic mutations for drug resistance in CML cells

(2012) Z Wang et al.   ONCOGENE

Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia

(2012) M. Jan et al.   Science Translational Medicine

Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease

(2012) A. Herrera-Merchan et al.   Nature Communications

VEGF/Neuropilin-2 Regulation of Bmi-1 and Consequent Repression of IGF-IR Define a Novel Mechanism of Aggressive Prostate Cancer

(2012) Hira Lal Goel et al.   Cancer Discovery

Bmi1 reprograms CML B-lymphoid progenitors to become B-ALL-initiating cells

(2011) A. Sengupta et al.   BLOOD

Activation of stress response gene SIRT1 by BCR-ABL promotes leukemogenesis

(2011) H. Yuan et al.   BLOOD

CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia

(2011) H. Makishima et al.   BLOOD

Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment

(2011) S. Chu et al.   BLOOD

Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease

(2011) J.-C. Chomel et al.   BLOOD

Polycomb genes and cancer: Time for clinical application?

(2011) Francesco Crea et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Assembling defenses against therapy-resistant leukemic stem cells: Bcl6 joins the ranks: Figure 1.

(2011) Francesca Pellicano et al.   JOURNAL OF EXPERIMENTAL MEDICINE

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

(2011) Christian Hurtz et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Expression patterns of microRNAs associated with CML phases and their disease related targets

(2011) Kateřina Machová Poláková et al.   Molecular Cancer

Polycomb Protein Ezh1 Promotes RNA Polymerase II Elongation

(2011) Kambiz Mousavi et al.   MOLECULAR CELL

BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR–ABL1 kinase inhibition

(2011) Cihangir Duy et al.   NATURE

Aberrant DNA Methylation Is Associated with Disease Progression, Resistance to Imatinib and Shortened Survival in Chronic Myelogenous Leukemia

(2011) Jaroslav Jelinek et al.   PLoS One

Aberrant methylation in promoter-associated CpG islands of multiple genes in chronic myelogenous leukemia blast crisis

(2011) EISUKE UEHARA et al.   Oncology Letters

BMI1 collaborates with BCR-ABL in leukemic transformation of human CD34+ cells

(2010) A. Rizo et al.   BLOOD

Effective Targeting of Quiescent Chronic Myelogenous Leukemia Stem Cells by Histone Deacetylase Inhibitors in Combination with Imatinib Mesylate

(2010) Bin Zhang et al.   CANCER CELL

A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo

(2010) Leandro C. Cerchietti et al.   CANCER CELL

Role of the polycomb group gene BMI1 in normal and leukemic hematopoietic stem and progenitor cells

(2010) Jan J Schuringa et al.   CURRENT OPINION IN HEMATOLOGY

BCL6 Canalizes Notch-Dependent Transcription, Excluding Mastermind-like1 from Selected Target Genes during Left-Right Patterning

(2010) Daisuke Sakano et al.   DEVELOPMENTAL CELL

The JARID2-PRC2 duality

(2010) H. M. Herz et al.   GENES & DEVELOPMENT

Jarid2 and PRC2, partners in regulating gene expression

(2010) G. Li et al.   GENES & DEVELOPMENT

Micro-RNA response to imatinib mesylate in patients with chronic myeloid leukemia

(2010) S. Flamant et al.   HAEMATOLOGICA

Chronic myeloid leukemia: mechanisms of blastic transformation

(2010) Danilo Perrotti et al.   JOURNAL OF CLINICAL INVESTIGATION

BMI1 Confers Radioresistance to Normal and Cancerous Neural Stem Cells through Recruitment of the DNA Damage Response Machinery

(2010) S. Facchino et al.   JOURNAL OF NEUROSCIENCE

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

(2010) François-Xavier Mahon et al.   LANCET ONCOLOGY

High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

(2010) J Boultwood et al.   LEUKEMIA

A Genome-wide screen identifies frequently methylated genes in haematological and epithelial cancers

(2010) Thomas Dunwell et al.   Molecular Cancer

Bmi1 Distinguishes Immature Retinal Progenitor/Stem Cells from the Main Progenitor Cell Population and Is Required for Normal Retinal Development

(2010) Wassim Chatoo et al.   STEM CELLS

Epidemiology of chronic myeloid leukaemia (CML)

(2009) Maren Rohrbacher et al.   BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY

Repression of BMI1 in normal and leukemic human CD34+ cells impairs self-renewal and induces apoptosis

(2009) A. Rizo et al.   BLOOD

AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

(2009) Thomas O'Hare et al.   CANCER CELL

Jumonji Modulates Polycomb Activity and Self-Renewal versus Differentiation of Stem Cells

(2009) Xiaohua Shen et al.   CELL

Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia

(2009) Edurne San José-Eneriz et al.   EUROPEAN JOURNAL OF CANCER

SUZ12 is a candidate target of the non-canonical WNT pathway in the progression of chronic myeloid leukemia

(2009) Luciana Pizzatti et al.   GENES CHROMOSOMES & CANCER

Timing and tuning of CD27-CD70 interactions: the impact of signal strength in setting the balance between adaptive responses and immunopathology

(2009) Martijn A. Nolte et al.   IMMUNOLOGICAL REVIEWS

MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations

(2009) Edurne San José-Enériz et al.   Molecular Cancer

A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo

(2008) L. C. Cerchietti et al.   BLOOD

Genetic and Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1 Oncogene Expression

(2008) María J. Bueno et al.   CANCER CELL

Toxicity Testing Moves from the Legislature to the Petri Dish—and Back

(2008) Trisha Gura   CELL

Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia

(2008) Jun Qian et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The role of the chromatin remodeler Mi-2  in hematopoietic stem cell self-renewal and multilineage differentiation

(2008) T. Yoshida et al.   GENES & DEVELOPMENT

Down-Regulation of hsa-miR-10a in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth

(2008) X. Agirre et al.   MOLECULAR CANCER RESEARCH

Ezh1 and Ezh2 Maintain Repressive Chromatin through Different Mechanisms

(2008) Raphael Margueron et al.   MOLECULAR CELL

Bmi1 is expressed in vivo in intestinal stem cells

(2008) Eugenio Sangiorgi et al.   NATURE GENETICS

Epigenetics in Cancer

(2008) Manel Esteller   NEW ENGLAND JOURNAL OF MEDICINE

Polycomb Repressive Complex 2 (PRC2) Restricts Hematopoietic Stem Cell Activity

(2008) Ian J Majewski et al.   PLOS BIOLOGY